American Society of Plastic Surgeons partners with PatientNow to provide the latest electronic medical record technology and patient engagement system

ARLINGTON HEIGHTS, Ill. – The American Society of Plastic Surgeons (ASPS) announced today a three-year Endorsement Agreement of PatientNOW, Inc., an electronic medical record, practice management and patient engagement system to be available to ASPS Member Surgeons. The agreement, which brings together the world’s largest specialty society of plastic surgeons with a comprehensive practice management software system for plastic surgery and aesthetic medical practices, will leverage both organizations’ respective strengths to develop and deliver the latest technological advances in electronic health records to plastic surgery practices.

“ASPS has a rich history of innovation in providing our members with practice management solutions that embrace emerging information technology tools,” said Robert X. Murphy, Jr, MD, President of the American Society of Plastic Surgeons. “Through strategic collaborations, we transform the delivery of healthcare throughout the specialty of plastic surgery while also providing our members with competitive pricing on leading edge information technology.”

“PatientNOW is proud to be endorsed by ASPS and the high standards of excellence they represent in the aesthetic and reconstructive plastic surgery industry,” said Jerry Jacobson, President and founder of PatientNOW.   “We are also excited to be a partner in bringing enhanced capability to member practices through new innovative software designed specifically for ASPS member surgeons.” Additionally, ASPS and PatientNOW have also entered into a strategic partnership where ASPS will collaborate with PatientNOW to:

•             Deliver more qualified prospective patients to each member surgeon through the Find-A-Surgeon integration.  This will consist of a Patient Consultation Scheduling Feature (PCSF) between ASPS’ Find a Surgeon web directory and PatientNOW’s EMR/PM/PAR software systems

•             Integrate the ASPS Patient Consent Library (PCL) into PatientNOW’s EMR, develop, test, deploy and maintain a PCSF and the integration of the PCL

•             Integrate ASPS web content, content from consent forms, ASPS videos, and other ASPS licensed content into PatientNOW systems

•             Deliver real time benchmark data to members

About ASPS

The American Society of Plastic Surgeons (ASPS) is the world's largest organization of board-certified plastic surgeons. Representing more than 7,000 Member Surgeons, the Society is recognized as a leading authority and information source on aesthetic and reconstructive plastic surgery. The ASPS is comprised of more than 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada. ASPS advances quality care to plastic surgery patients by encouraging high standards of training, ethics, physician practice and research in plastic surgery. For more information, please visit www.plasticsurgery.org.

About PatientNOW

PatientNOW is more than an EMR provider.  PatientNOW created a patient engagement system designed to capture new patients, retain existing patients and grow practice revenue through automated workflow. Designed specifically for aesthetic medical practices, PatientNOW is in the top 100 EHRs in the U.S. and is celebrating 10 years of providing aesthetic medical practices with a proven method of building their business through automated systems that frees staff from manual tasking. More information on PatientNOW can be found at www.patientnow.com or by calling 800-436-3150.

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.